

PRESS RELEASE

A big step for Oasmia in Barcelona

This Thursday results from a phase I/II study with the cancer drug Paclical® was presented at the European Cancer Conference (ECCO 14) in Barcelona.

- Paclical® is a new interesting cancer drug. Compared to conventional therapy with paclitaxel Paclical® can be given in a shorter time and without preventive medication against hypersensitivity reactions, says Niklas Loman at Lunds University Hospital, principal investigator for the clinical study.

The results of the study and the generated interest for Paclical® at the conference in Barcelona is a big step forward for Oasmia and confirms further the company's strong product portfolio.

More information is available at www.ngm.se or www.oasmia.com

For further information please contact: info@oasmia.com or call: +46 (0) 18 50 54 40

Oasmia Pharmaceutical is a pharmaceutical company that specialises in the treatment of severe diseases. A pharmaceutical company based on the latest concepts in bio-organic chemistry. The main idea is to improve the treatment of serious diseases. Primarily, this development is in oncology and treatment with cytostatics but Oasmia also conducts research in antibiotics, asthma and neurological diseases. Oasmia has in-house production capacity of pharmaceuticals for clinical trials, both company related and others. Oasmia has developed several products based on existing pharmaceuticals in a new environment, which leads to whole new solutions for cancer treatment. These products give Oasmia a solid product portfolio within oncology with several products in clinical or pre-clinical phase. Oasmia is listed on NGM Equity.